SOURCE: Five Star Equities
NEW YORK, NY--(Marketwire - May 8, 2012) - Dividends have been a major source of investment gains in the market for many years. With interest rates as low as they are currently long term investors have been looking to high yielding dividend stocks as safe havens. In 2012 S&P companies are on pace to pay out a record amount in dividends. Five Star Equities examines the outlook for Dividend paying stocks and provides equity research on General Electric Company (NYSE: GE) and Pfizer Inc. (NYSE: PFE).
Access to the full company reports can be found at:
S&P companies are set to pay out a record of $279 billion in dividends in 2012, up nearly 16 percent from 2011. There are currently more dividend payers on the S&P index then there has been in over a decade. According to S&P analyst Howard Silverblatt 401 of the S&P 500 now pay dividends. "At this point, taxes are my main concern for dividends," Silverblatt wrote last month, noting that dividend taxes could nearly triple next year from the 15 percent today to 43.4 percent next year. "From a planning perspective, this will force corporations to reexamine their return-to-shareholders policy, potentially pulling back on dividend increases and increasing share buybacks."
Five Star Equities releases regular market updates on Dividend paying stocks so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
General Electric currently offers investors an annual dividend of $0.68, a yield of 3.52 percent. GE and XD Electric Group recently announced the formation of a new partnership to deliver a full-line of electric transmission and distribution (T&D) and grid automation solutions to customers around the world. The partnership creates a new global competitor to provide customers with proven technology offerings to build and upgrade their electrical infrastructure to meet the high demand for reliable electricity.
Pfizer currently offers investors an annual dividend of $0.88, a yield of 3.93 percent. Pfizer and Protalix BioTherapeutics, Inc. recently announced that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: